ACB
Price
$4.91
Change
+$0.08 (+1.66%)
Updated
Sep 5 closing price
Capitalization
276.48M
61 days until earnings call
PAHC
Price
$39.45
Change
+$0.38 (+0.97%)
Updated
Sep 5 closing price
Capitalization
1.6B
60 days until earnings call
Interact to see
Advertisement

ACB vs PAHC

Header iconACB vs PAHC Comparison
Open Charts ACB vs PAHCBanner chart's image
Aurora Cannabis
Price$4.91
Change+$0.08 (+1.66%)
Volume$819.6K
Capitalization276.48M
Phibro Animal Health
Price$39.45
Change+$0.38 (+0.97%)
Volume$480.72K
Capitalization1.6B
ACB vs PAHC Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. PAHC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and PAHC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ACB: $4.91 vs. PAHC: $39.45)
Brand notoriety: ACB: Notable vs. PAHC: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 57% vs. PAHC: 140%
Market capitalization -- ACB: $276.48M vs. PAHC: $1.6B
ACB [@Pharmaceuticals: Generic] is valued at $276.48M. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.6B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 7 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 7 bullish, 4 bearish.
  • PAHC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ACB is a better buy in the short-term than PAHC.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -9.41% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +6.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

PAHC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PAHC($1.6B) has a higher market cap than ACB($276M). PAHC has higher P/E ratio than ACB: PAHC (33.15) vs ACB (21.12). PAHC YTD gains are higher at: 90.357 vs. ACB (15.529). ACB has less debt than PAHC: ACB (102M) vs PAHC (762M).
ACBPAHCACB / PAHC
Capitalization276M1.6B17%
EBITDA26.6MN/A-
Gain YTD15.52990.35717%
P/E Ratio21.1233.1564%
Revenue358MN/A-
Total Cash140MN/A-
Total Debt102M762M13%
FUNDAMENTALS RATINGS
ACB vs PAHC: Fundamental Ratings
ACB
PAHC
OUTLOOK RATING
1..100
2222
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
10037
SMR RATING
1..100
9364
PRICE GROWTH RATING
1..100
6136
P/E GROWTH RATING
1..100
82100
SEASONALITY SCORE
1..100
7549

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (29) in the Pharmaceuticals Major industry is in the same range as ACB (58) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to ACB’s over the last 12 months.

PAHC's Profit vs Risk Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for ACB (100) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than ACB’s over the last 12 months.

PAHC's SMR Rating (64) in the Pharmaceuticals Major industry is in the same range as ACB (93) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to ACB’s over the last 12 months.

PAHC's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ACB (61) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to ACB’s over the last 12 months.

ACB's P/E Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as PAHC (100) in the Pharmaceuticals Major industry. This means that ACB’s stock grew similarly to PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBPAHC
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
61%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 1 day ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 5 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PARNX62.140.88
+1.44%
Parnassus Mid Cap Growth Investor
PSLAX16.690.07
+0.42%
Putnam Small Cap Value A
FBMPX139.43N/A
N/A
Fidelity Select Communication Services
MGQIX18.15N/A
N/A
Morgan Stanley Inst Global Stars I
JMVPX36.06N/A
N/A
JPMorgan Mid Cap Value R3

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.66%
CGC - ACB
64%
Loosely correlated
+5.80%
OGI - ACB
63%
Loosely correlated
+2.48%
CRON - ACB
54%
Loosely correlated
N/A
TLRY - ACB
53%
Loosely correlated
+3.48%
PAHC - ACB
31%
Poorly correlated
+0.97%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+0.97%
AMRX - PAHC
46%
Loosely correlated
+0.73%
ZTS - PAHC
41%
Loosely correlated
+0.08%
PBH - PAHC
38%
Loosely correlated
-2.55%
ELAN - PAHC
37%
Loosely correlated
+5.50%
VTRS - PAHC
36%
Loosely correlated
+1.65%
More